Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3097–3120 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Breast Cancer Diagnosis
Interventions: Fine needle aspiration, Cancer Detection cartridge; Procedure · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Lutherville-Timonium, Maryland

Conditions: NODULOCYSTIC ACNE
Interventions: Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets; Drug
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more

Conditions: Breast Cancer, Lung Cancer
Interventions: ACCURE Navigator, Usual Care by Cancer Center Care Team; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Greensboro, North Carolina • Pittsburgh, Pennsylvania

Conditions: Xeroderma Pigmentosum
Interventions: Survey Study; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Psoriasis, Cardiovascular Diseases
Interventions: Apremilast; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Rockville, Maryland • Buffalo, New York + 4 more

Conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions: Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel; Drug
Lead sponsor: bioRASI, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more

Conditions: HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Capecitabine, Cixutumumab, Lapatinib Ditosylate, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 390
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 274 more

Conditions: Melanoma
Interventions: Ipilimumab (BMS-734016), Vemurafenib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Critical Limb Ischemia, Ischemia, Leg Ulcer
Interventions: pVGI.1 (VEGF-2); Genetic
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years and older
Timeline: Ends 2008
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Unresected Stage IIIb to IVM1c Melanoma
Interventions: Talimogene Laherparepvec; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 18 more

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more

Conditions: Breast Cancer
Interventions: immunohistochemistry staining method, lymphangiography, sentinel lymph node biopsy, therapeutic conventional surgery, whole breast irradiation; Other · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 113
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 83 more

Conditions: Breast Cancer (Advanced/Metastatic), ER Positive
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Taking Charge during Treatment (TCT) Intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Wauwatosa, Wisconsin

Conditions: Healthy Volunteers, Psoriasis
Interventions: PBI-100 Topical Cream, Vehicle Cream; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Melanoma
Interventions: NKTR-214, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Stanford, California + 20 more

Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
Interventions: CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab; Drug
Lead sponsor: CellCentric Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Psoriasis
Interventions: Secukinumab, Placebo followed by Secukinumab; Drug
Lead sponsor: James G. Krueger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne
Interventions: Spironolactone, Doxycycline Hyclate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Fort Smith, Arkansas • San Francisco, California • Sherman Oaks, California + 13 more

Conditions: Breast Neoplasms, Tamoxifen
Interventions: Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs; Other
Lead sponsor: Medco Health Solutions, Inc.; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Franklin Lakes, New Jersey

Conditions: Urticaria
Interventions: Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab; Dietary Supplement · Drug
Lead sponsor: Selina Gierer, D.O.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Diabetic Foot Ulcers (DFU), Venous Stasis Ulcers (VSU)
Interventions: OASIS Wound Matrix; Device
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Fort Smith, Arkansas • St Louis, Missouri • St. George, Utah

Conditions: Neoplasms, Breast Cancer
Interventions: PF-06650808; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Santa Monica, California • Columbus, Ohio + 1 more

Search by objective public record fields.

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Automated Method for Breast Cancer Detection

Finasteride Treatment of Severe Nodulocystic Acne

Accountability for Cancer Care Through Undoing Racism and Equity

Xeroderma Pigmentosum Patient Experiences

Vascular Inflammation in Psoriasis - Apremilast

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

VEGF Gene Transfer for Critical Limb Ischemia

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer

Blood Biomarkers for Breast Cancer Treatment Response

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Study to Evaluate CCS1477 in Advanced Tumours

Safety and Efficacy of Secukinumab in Mild Psoriasis

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

OASIS Wound Matrix (Oasis) Mechanism of Action

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors